Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
CTRV Stock Trend
The stock lies in the middle of a wide and weak rising trend in the short term and a further rise within the trend is signaled.
Given the current short-term trend, the stock is expected to rise 7.76% during the next 3 months and, with a 90% probability hold a price between $1.15 and $1.39 at the end of this 3-month period.
WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.
Data
| Date | Bottom | Mid | Top |
|---|---|---|---|
| 2022-05-23 | $1.07 | $1.18 | $1.29 |
| 2022-05-24 | $1.07 | $1.18 | $1.29 |
| 2022-05-25 | $1.08 | $1.18 | $1.29 |
| 2022-05-26 | $1.08 | $1.19 | $1.29 |
| 2022-05-27 | $1.08 | $1.19 | $1.29 |
| 2022-05-31 | $1.08 | $1.19 | $1.30 |
| 2022-06-01 | $1.08 | $1.19 | $1.30 |
| 2022-06-02 | $1.08 | $1.19 | $1.30 |
| 2022-06-03 | $1.08 | $1.19 | $1.30 |
| 2022-06-06 | $1.09 | $1.19 | $1.30 |
| 2022-06-07 | $1.09 | $1.20 | $1.30 |
| 2022-06-08 | $1.09 | $1.20 | $1.31 |
| 2022-06-09 | $1.09 | $1.20 | $1.31 |
| 2022-06-10 | $1.09 | $1.20 | $1.31 |
| 2022-06-13 | $1.09 | $1.20 | $1.31 |
| 2022-06-14 | $1.10 | $1.20 | $1.31 |
| 2022-06-15 | $1.10 | $1.21 | $1.31 |
| 2022-06-16 | $1.10 | $1.21 | $1.31 |
| 2022-06-17 | $1.10 | $1.21 | $1.32 |
| 2022-06-21 | $1.10 | $1.21 | $1.32 |
| 2022-06-22 | $1.10 | $1.21 | $1.32 |
| 2022-06-23 | $1.10 | $1.21 | $1.32 |
| 2022-06-24 | $1.11 | $1.21 | $1.32 |
| 2022-06-27 | $1.11 | $1.22 | $1.32 |
| 2022-06-28 | $1.11 | $1.22 | $1.33 |
| 2022-06-29 | $1.11 | $1.22 | $1.33 |
| 2022-06-30 | $1.11 | $1.22 | $1.33 |
| 2022-07-01 | $1.11 | $1.22 | $1.33 |
| 2022-07-05 | $1.12 | $1.22 | $1.33 |
| 2022-07-06 | $1.12 | $1.22 | $1.33 |
ContraVir Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. The company is developing CMX157 and CRV431 to treat HBV infection; and FV-100, an orally available, small molecule compound for the prevention of post-herpetic neuralgia, and treatment of herpes zoster infection and acute zoster-associated pain. Contr... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
